**β₁-Blockers Enhance Inotropy of Endogenous Catecholamines in Chronic Heart Failure**

**Thomas J. Feuerstein**¹,²* and **Eberhard Schlicker**³

¹ Sektion für Neuroelektronische Systeme, Klinik für Neurochirurgie, Universität Freiburg, Breisgau, Germany, ² Freiburg Institute for Advanced Studies, Albert-Ludwigs-Universität Freiburg and Institut für Pharmakologie und Toxikologie, Universität Bonn, Bonn, Germany, ³ Institut für Pharmakologie und Toxikologie, Universität Bonn, Bonn, Germany

Although β₁-blockers impressively reduce mortality in chronic heart failure (CHF), there are concerns about negative inotropic effects and worsening of hemodynamics in acute decompensated heart failure. May receptor theory dispel these concerns and confirm clinical practice to use β₁-blockers? In CHF, concentrations of catecholamines at the β₁-adrenoceptors usually exceed their dissociation constants (Kₐ). The homodimeric β₁-adrenoceptors have a receptor reserve and display negative cooperativity. We considered the binomial distribution of occupied receptor dimers with respect to the interaction of an exogenous β₁-blocker and elevated endogenous agonist concentrations > [Kₐ], corresponding to an elevated sympathetic tone. Modeling based on binomial distribution suggests that despite the presence of a low concentration of the antagonist, the activation of the dimer receptors is higher than that in its absence. Obviously, the antagonist improves the ratio of the dimer receptors with only single agonist activation compared with the dimer receptors with double activation. This leads to increased positive inotropic effects of endogenous catecholamines due to a β₁-blocker.

To understand the positive inotropic sequel of β₁-blockers in CHF is clinically relevant. This article may help to eliminate the skepticism of clinicians about the use of β₁-blockers because of their supposed negative inotropic effect, since, on the contrary, a positive inotropic effect can be expected for receptor-theoretical reasons.

**Keywords:** chronic heart failure, sympathetic tone, homodimer, negative cooperativity, binomial distribution, receptor reserve

**INTRODUCTION**

β-Adrenoceptors (β-ARs) are activated by the catecholamines noradrenaline (NA) and adrenaline (A), and are members of the adrenoceptor family of the seven-transmembrane superfamily of receptors. There are three β-AR subtypes: β₁, β₂, and β₃. Activation of adenylyl cyclase through the guanine nucleotide-binding regulatory protein Gₛ is the classic, but not the only, mechanism of β-AR action (1). Cardiac β₁-ARs increase the heart rate, myocardial contractility, impulse conduction, and pacemaker activity. They represent 75–80% of the total β-AR density in human adult cardiac myocytes (2). β₂-ARs (3–5) comprise about 15–18%, and the remaining 2–3% is β₃-AR (2).
Many years (easy to understand and has been considered a contradiction for bisoprolol, carvedilol, metoprolol succinate, and nebivolol) of bisoprolol, carvedilol, metoprolol succinate, and nebivolol. Moreover, they lead to an induced sympatholysis (following conditions:

Heart failure (CHF) (Feuerstein and Schlicker). A leading textbook has stated still in 1996 that it is unclear whether β-blockers improve survival in heart failure patients (10). Apart from the unavailability of large clinical studies at that time, one reason for the skepticism against the use of β-blockers in CHF may have been the absence of a convincing, pathophysiologically founded, rationale for this use.

In the meantime, some β-blockers have become a standard strategy to increase survival in CHF. Guidelines suggest the use of bisoprolol, carvedilol, metoprolol succinate, and nebivolol for this purpose (6–8). The latter is effective in patients >70 years only, and a positive effect has been shown for the combined endpoint of survival or hospitalizations only (11). The former three drugs had similar effects on all-cause mortality among patients with CHF in a study on 6,010 outpatients with stable CHF and a reduced left ventricular ejection fraction (12).

The beneficial effect of β1-blockers is mainly ascribed to the following conditions:

- Negative chronotropy; among others, they reduce the incidence of atrial fibrillation and control ventricular rate (7).
- They protect the heart against left ventricular remodeling elicited by endogenous catecholamines via β1-adrenoceptors (13, 14).
- They protect the heart indirectly via inhibition of the renin–angiotensin cascade (15).
- β1-Blockers antagonize anti-β1-AR antibodies constitutively stimulating β1-ARs (16).
- Moreover, they lead to an induced sympatholysis (2).

The therapeutic rationale to use β1-blockers in CHF is not easy to understand and has been considered a contradiction for many years (11). One reason, for instance, is the doubtfulness whether the abovementioned negative chronotropic effect can compensate for the simultaneous negative inotropic effect to be expected, at first glance, under β1-AR blockade (11). The well-known β1-AR downregulation in CHF (17) suggests that β1-ARs play a major role in the development of CHF.

Here, we provide evidence that positive, not negative, inotropic effects may occur in CHF patients treated with a low concentration of a β1-AR antagonist.

METHODS

To understand how the binomial distribution solves the riddle of negative inotropic β1-blockers inducing positive inotropic effects, two fundamental properties of β1-ARs in the human heart must be recalled.

First, β1-ARs have a receptor reserve (spare receptors) (18–20); in other words, the concentrations of catecholamines (the endogenous agonists at β1-ARs) that produce the half-maximum effects (EC<sub>50</sub>s) are lower than their dissociation constants K<sub>D</sub> at the β1-ARs. Note that during CHF, the concentration of the endogenous agonists at the β1-AR may even exceed their K<sub>D</sub>s (21–23). For the sake of simplicity, the endogenous catecholamines are called endogenous agonist below with a single K<sub>D</sub> only.

Second, β1-ARs may occur as homodimers (24, 25). To activate G proteins, a pentameric structure constituted of one GPCR homodimer and one heterotrimeric G protein may provide the main functional unit (26). The colocalization between two β1-AR particles is transient; dimerization increases with receptor density (24). However, the dimers are stable over a 10-fold range of receptor expression levels (27). Agonist stimulation does neither alter receptor dimerization nor lateral mobility within the cellular membrane (24). It is the TM5 interface of the ligand-free β1-AR that can partner with TM4 or TM6, depending on the conformation of the dimeric receptors. However, an agonist-induced receptor–G protein interaction depends on rearrangements of TM5 and TM6 within the seven-helical domain bundle, which may suggest that dimerization occurs between the partners TM4 and TM5, leaving TM6 for G protein interaction behind (26).

In addition, agonist activation of one subunit (protomer) is sufficient to induce the inotropic response obtained from this dimer: Ligand occupancy to the first protomer is enough to produce a significant G protein activation and functional response (26), and the binding of the endogenous agonist to the second subunit is negatively influenced after the first one has been occupied [negative cooperativity, (25)]. Here, negative cooperativity means that the binding of an agonist to the first protomer decreases the affinity of the agonist for the second one: Both protomers of a homodimer contribute to the allosteric modulation, and the same ligand is the allosteric modulator (binding to the first protomer) and the modulated target (binding to the second protomer). This may result in two different levels of ligand-mediated signaling that would depend on the concentration of the ligand. Thus, negative cooperativity could provide a mechanism that protects the biologic system against acute elevations of an endogenous agonist (26).

The Binomial Distribution Describes the Occupancy of the Dimeric β1-Spare Receptors

The total number of receptors per dimer is n = 2. The number of occupied receptors is i = 0, 1, or 2; i = 1 is the (minimal) number of β1-ARs of a dimer that must be activated to obtain a maximum agonist effect of this dimer. Thus, half of the dimer receptors are spare receptors.

If 0 < i ≤ n, or 0 < i, 2 ≤ 2, the number i of occupied receptors has a binomial distribution B(n, q) with parameters n = 2 and q (Box 1).

For i = 0, no receptor of the dimer is occupied; for i = 1 or 2, one or two receptors are occupied, respectively. “q” is the fractional receptor occupation, i = [L] / [L] + K<sub>D</sub> + K<sub>D</sub>, with L representing the β1-AR ligand (agonist or antagonist), [L] its concentration, and K<sub>D</sub> the dissociation constant of the ligand (K = K<sub>D</sub> for an agonist,
The binomial distribution indicates the number of successes in a sequence of \( n \) independent experiments, each asking a yes–no question. In our context, yes is a single binding success to a receptor dimer; no means absence of binding. A receptor dimer only allows \( n = 2 \) independent experiments. The first experiment refers to the first receptor, the second to the second receptor, to be occupied or not. The binding success at each receptor has the probability \( q \). The binomial distribution, \( B(n, q) \), equals \( \binom{n}{i} q^i (1-q)^{n-i} \).

\[
\binom{n}{i} = \frac{n!}{i!(n-i)!}; \text{ thus, for } i = 0, 1, 2 \text{ and } n = 2, \binom{2}{0} = 1, \binom{2}{1} = 2, \text{ and } \binom{2}{2} = 1. \text{ } i \text{ successes occur with probability } q^i, \text{ and } n-i \text{ failures occur with probability } (1-q)^{n-i}. \text{ However, the } i \text{ successes can occur anywhere among the two trials, and there are } \binom{2}{i} \text{ different ways of distributing } i \text{ successes in a sequence of two trials: One way only to distribute the absence of occupations on both dimer receptors, two ways for occupying the first and leaving the second free or leaving the first free and occupying the second, again only one way to distribute two occupations among two receptors.}

\[\text{Example: Let us say you roll six times with a normal die. What is the probability that the 6 will be rolled four times? The answer is } \binom{6}{4} \left(\frac{1}{6}\right)^4 \left(\frac{5}{6}\right)^2 = 0.008. \text{ Thus, this probability is 0.8%.}\]

\[K = K_A \text{ for an antagonist). Figure 1 represents diagrams with } \frac{[L]}{K+L} \text{ on the x-axis and B(2, q)} \text{ on the y-axis.}\]

**The Binomial Occupancy May Be Exemplified by a Pure Antagonist as Ligand of \( \beta_1 \)-ARs**

\(K_A\) of a pure (neutral) \( \beta_1 \)-blocker is \( 10^{-7} \text{ M} \) [e.g., metoprolol, (22)]. Using this drug at a concentration of \( 10^{-7} \text{ M} \) then yields \( q = \frac{[L]}{K_A} = 0.5 \), and the following distributions ensue:

- No receptor occupied: With \( \binom{n}{i} q^i (1-q)^{n-i} \), the probability that no receptor is occupied (\( n = 2 \) and \( i = 0 \)) is 25%;
  \[\binom{2}{0} 0.5^0 (1-0.5)^2 = 1 \cdot 1 \cdot (0.5) = 0.25 \text{ according to } \frac{1}{4} (1-q)^2 = (1-q^2).\]

- Thus, 25% of all dimers have no blocked receptor and can be activated by an endogenous \( \beta_1 \)-AR agonist occupying at least one receptor of each dimer (see Figure 1A, dashed purple curve, where \( \frac{[L]}{K+L} = 0.5 \) on the x-axis corresponds to 25% on the y-axis).

One \( \beta_1 \)-AR blocked and one non-occupied: 50%.

\[\binom{2}{1} 0.5^1 (1-0.5)^2 = 2 \cdot 0.5 \cdot 0.5 = 0.5 \text{ according to } \frac{1}{4} (1-q)^2 = 2 \cdot q \cdot (1-q) \text{ (see Figure 1A, black curve, where } \frac{[L]}{K+L} = 0.5 \text{ on the x-axis corresponds to 50% on the y-axis).}\]

Both \( \beta_1 \)-ARs blocked: 25%; these are not accessible for agonists.

\[\binom{2}{2} 0.5^2 (1-0.5)^2 = 1 \cdot 0.25 \cdot 1 = 0.25 \text{ according to } \frac{1}{4} (1-q)^2 = q^2 \text{ (see Figure 1A, dashed blue curve at } q = 0.91 \text{). The sum of both the black curve, depicting the condition "one of two receptors is occupied" and the dashed blue curve, depicting the condition "two of two receptors are occupied" yields the gray curve in Figure 1A. This sum corresponds to a receptor reserve of 50% since the activation of one receptor leads to the same maximum effect from the respective dimer as does the activation of both dimer receptors. This assumed amount of receptor reserve of 50% only in the human heart corresponds to the findings of Brown et al. (19) who stated that in the human heart, receptor reserve was rather low and declined further with an increasing degree of heart failure (see also Box 2). The two conditions mentioned, represented by the gray curve in Figure 1A, will be translated into inotropy when the signal of agonist occupation of one or two dimer receptors is transduced.\]

The presence of \( 10^{-7} \text{ M} \) of the pure antagonist increases the agonist \( K_D \) with \( q = \frac{[L]}{K_A + [L]} \).

For explanation, the sum of exponents in \( 10^{-7-8+7} + 7 \) in the denominator corresponds to \( 10 \log_{10} ([\text{endogenous agonist}] + [L]K_A) \).

\[\text{with } Lg = \log_{10} \text{, see equation 1 in Mantovani et al. (35), which is based on the Cheng and Prusoff (36) equation. Thus, at } 10^{-7} \text{ M, the antagonist doubles the endogenous agonist } K_D \text{ of } 10^{-8} \text{ M, thereby diminishing } q. \text{ There is no other influence of the}\]

RESULTS AND DISCUSSION

How can we now explain that the presence of a pure (neutral) \( \beta_1 \)-AR antagonist enhances the action of the endogenous agonist? This will be discussed below, using a \( K_D \) value for the endogenous \( \beta_1 \)-AR agonist of \( 10^{-8} \text{ M} \) [28], see also Box 2] and a \( K_A \) value for the pure antagonist of \( 10^{-7} \text{ M} \) (see above).

**Occupancy by the Endogenous \( \beta_1 \)-AR Agonist Alone or in the Presence of the Pure Antagonist**

In the absence of pure antagonist, the term \( q = \frac{[L]}{[K_A]} \) will be, at [endogenous agonist] = \( 10^{-7} \text{ M} \), \( \frac{[L]}{[K_A] + [L]} = 0.91 \). This means that 91% of \( \beta_1 \)-ARs of all dimers are occupied by the endogenous \( \beta_1 \)-AR agonist, either by only one agonist molecule (yielding \( \frac{1}{4} 0.91^1 (1-0.91)^{2-1} = 16.4\% \), see Figure 1A, black curve at \( q = 0.91 \)) or by two agonist molecules [yielding \( \frac{2}{4} 0.91^2 (1-0.91)^{2-2} = 82.8\% \), see Figure 1A, dashed blue curve at \( q = 0.91 \)]. The sum of both the black curve, depicting the condition “one of two receptors is occupied” and the dashed blue curve, depicting the condition “two of two receptors are occupied” yields the gray curve in Figure 1A. This sum corresponds to a receptor reserve of 50% since the activation of one receptor leads to the same maximum effect from the respective dimer as does the activation of both dimer receptors. This assumed amount of receptor reserve of 50% only in the human heart corresponds to the findings of Brown et al. (19) who stated that in the human heart, receptor reserve was rather low and declined further with an increasing degree of heart failure (see also Box 2). The two conditions mentioned, represented by the gray curve in Figure 1A, will be translated into inotropy when the signal of agonist occupation of one or two dimer receptors is transduced.
FIGURE 1 | Binomial distribution and possible translation into inotropy of β1-AR ligand binding at dimer receptors without consideration of negative cooperativity (A) and with consideration of negative cooperativity (B). Usually, concentration–response curves with log concentrations on the abscissa are used; here the x-axis is

(Continued)
antagonist on the curves of Figure 1 than to increase the agonist $K_D$, i.e., to shift $q$ to the left.

**Receptor Theory Finally Translates Agonist Occupation of Dimer Receptors Into Inotropy**

The probabilities that, at different agonist and antagonist concentrations, no receptor, one of two receptors, or both receptors of the dimers are activated can be calculated. Table 1 displays agonist binding probabilities at the dimer receptors in the absence and presence of the $\beta_1$-AR antagonist administered at a concentration ($10^{-7}$ M) that equals its $K_A$ value (note that in Table 1, agonist concentrations are given in $\mu$M for better distinctness).

Agonist binding to at least one dimer receptor is the basis of the translation of agonist occupation into inotropy. If one considers a simplified scenario (negative cooperativity neglected), the gray curve of Figure 1A yields the translation into inotropy as calculated in Table 1A. The presence of an antagonist decreases the activation probability at any agonist concentration since the blue curve is rising steadily. The absence of a maximum followed by a declining part of this blue curve excludes that the antagonist can lead to a

---

**FIGURE 1** | characterized by the probability $q$ of binding instead. “$q$,” i.e., the fractional receptor occupation $\frac{q}{1+q}$, corresponds to the relative frequency of binding, which depends on the concentration of the ligand $[L]$. Ligand binding, i.e., the agonist and its interaction with the antagonist, then translates into inotropy according to the binomial distribution. (A) The dashed purple curve, which indicates the probability that no dimer receptor is occupied, does – of course – not translate into inotropy. The black and the dashed blue curves, however, reflect the presence of an agonist and, therefore, translate into inotropy. The gray curve is the sum of the black and the dashed blue curve and reflects a 50% receptor reserve since the activation of one of two dimer receptors yields the same maximum effect (at $q = 1$) as the activation of two receptors. (B) The presence of an antagonist changes the inotropic effect of agonist binding. $q^2/2$ has been used to model the fact that binding to the first receptor is already sufficient to obtain the maximum response, whereas the second receptor does not contribute any further (dashed blue curve without antagonist interaction). The latter curve and the curve for activation of one receptor only (black curve) add to the solid blue curve. Now the antagonist effect comes into play. The blue arrow shows that at $q > 0.67$, the $\beta_1$-AR antagonist – by shifting the curve to the left (see blue arrow) – can increase inotropy. Another modeling of negative cooperativity reflects the condition that the functionally relevant first binding event extends to all dimers covered by the condition “both dimer receptors occupied,” which leads to $q^2 - 2q(1 - q)$ (dashed brown curve). The latter curve and the curve for activation of one receptor only (black curve) add to the solid brown curve. Again, the antagonist effect comes into play here. The brown arrow indicates the extent of possible inotropy increase. An increase in inotropy is only possible at $q > 0.61$.

---

**BOX 2** | Searching for the $K_D$ value of NA and A

- The plasma concentrations of the endogenous catecholamines, [NA] and [A], measured in controls and heart transplant recipients (28) were in the low nanomolar range (Table below). Considering the catecholamine concentrations of 487 and 2.599 ng/mL in both groups, Ferretti et al. (29) obtained a $\beta_1$-adrenoceptor affinity constant for the catecholamines of $\sim$487/176.2 ng/mL = 2.76 nM for the controls and $\sim$2.599/176.2 ng/mL = 14.75 nM for heart transplant recipients (with 176.2 being the mean of the molecular weights of NA and A) (Table). Thus, our assumed $K_D$ of 10 nM for the endogenous agonists seems realistic, at least in the light of the available literature on the human heart.

- The paper by Baker (29) yielded micromolar $K_D$ s, i.e., $\sim$100-fold lower $EC_{50}$ for NA and A than assumed, suggesting a very high receptor reserve (Table). These values were obtained in binding experiments in whole CHO cells stably expressing human $\beta_1$-adrenoceptors resembling the low-affinity sites detected in membranes in the presence of GTP. For comparison, Hoffmann et al. (22) studied binding affinities of agonists in the presence of 100 $\mu$M GTP. This non-physiological addition again yielded micromolar $K_D$s of NA and A, which, however, do not display the real $K_D$s of the endogenous agonists at physiological $\beta_1$-adrenoceptors.

- By the way, an extremely high receptor reserve, which has to explain a factor of $\sim$100 between $EC_{50}$ and $K_D$ is highly unlikely: One has to emphasize that the classical calculation of concentration–response curves of spare receptors according to the operational model of Black and Leff (33) is misleading (see, for instance, (31–33]). Thus, we do not assume such a high $\beta_1$-adrenoceptor reserve in the human heart. In addition, the affinity shift between the $\beta_1$-adrenoceptor-rich controls and the $\beta_1$-adrenoceptor-poorer heart transplant recipients, corresponding to $L_g (14.75/2.76) = 0.73$ $L_g$-units, would correspond to a decrease in spare receptors from about 75% to 25%; see Figure 4 of Feuerstein et al. (34). The assumed receptor reserve of 50% in the manuscript complies with this order of magnitude.

---

| Catecholamine concentration (nM) | $\beta_1$-adrenoceptor affinity constant ($K_D$, nM)$^*$ | $\beta_1$-adrenoceptor potency ($EC_{50}$, nM)$^*$ |
|-------------------------------|-------------------------------|-------------------------------|
| Noradrenaline | Adrenaline | Noradrenaline | Adrenaline |
| **In vivo** | Controls | Ferretti et al. (29) | 1.63 | 2.76$^*$ | 0.55 | 1.48 |
| Heart transplant recipients | 8.31 | 14.75$^*$ |
| **In vitro** | CHO cells | Baker (29) | 1,820$^*$ | 7,080$^*$ |
| | Hoffmann et al. (22) | 11.48$^*$ | 24.55$^*$ |
| | | 3,570$^*$ | 3,970$^*$ |

Let us assume that 3,570 nM would be the correct $K_D$ for NA and that 11.48 nM would be the correct $EC_{50}$. Thus, a corresponding spare receptor-induced shift was $L_g (3,570/11.48) = 2.49$ $L_g$-units. A translation of this shift into a degree of receptor reserve according to Feuerstein et al. (34) estimates 1,000 $\beta_1$-adrenoceptors per heart myocyte, being the so-called functional unit, and 999 spare receptors. Thus, the activation of 1 of 1,000 adrenoceptors per myocyte would suffice to induce a maximum inotropic response. Thus, linking a binding $K_D$ with a functional $EC_{50}$ seems unrealistic.
higher level of the fractional receptor occupation $q$ on the y-axis. In other words, without negative cooperativity between the dimer receptors, a $\beta_1$-blocker cannot induce a positive inotropic effect.

**Positive Inotropy in the Presence of a $\beta_1$-Blocker Requires Negative Cooperativity**

Obviously, negative cooperativity has to be taken into account, i.e., that binding of one $\beta_1$-AR agonist molecule to the first dimer receptor, which already induces the maximum inotropic response from this dimer, reduces the binding of the second agonist molecule to the partner receptor. The question is only how this negative cooperativity in the case of "two of two receptors occupied" can be modeled in the binomial distribution of dimer receptor binding. How must the dashed blue curve of Figure 1A be changed to reflect negative cooperativity?

**Possible Modeling of Negative Cooperativity**

The binding reduction of the second agonist molecule diminishes the overall dimeric binding, i.e., at $q = 1$ on the x-axis, $q^2$ (meaning that both $\beta_1$-ARs are occupied) on the y-axis must be lower. Negative cooperativity may be expressed, for instance, by $q^2/2$ since agonist binding to the first dimer receptor is already sufficient to obtain the maximum response and since binding to the second receptor does not contribute to the response. The dashed blue curve in Figure 1B represents these probabilities of $q^2/2$. In this case, the sum of the dashed blue curve and of the black curve, i.e., the solid blue curve in Figure 1B, has a clear maximum at about $q = 0.67$. At this $q$ value, the agonist concentration is $2.03 \cdot [K_D]$ ($q = 0.67 = [0.0203]$. At agonist concentrations higher than $2.03 \cdot [K_D]$, the inotropic efficiency decreases again. Note that an antagonist-induced shift of $q$ to the left at $q > 0.67$ on the x-axis increases the corresponding y-value.

By contrast, if the $\beta_1$-blocker is used at a concentration that reduces the fractional receptor occupation to $q < 0.67$, an increase in positive inotropy is impossible.

Table 1B contains the beneficial condition. At an antagonist concentration equaling the $K_A$, the corresponding inotropies may be increased. Thus, for concentrations of the endogenous agonist $\geq 0.032 \mu M$ (being larger than $K_D$) and corresponding to an elevated sympathetic tone, the agonist occupation in the presence of the antagonist is higher than that in its absence (see < signs).

Other modelings of negative cooperativity than $q^2 \to q^2/2$ in the case of “two of two receptors occupied” are conceivable. In any case, negative cooperativity in the B(2, q)-curve must be represented by a declining part after a maximum. One additional modeling possibility may be:

Since the first binding event within each dimer already induces the maximum inotropic response, this relevant first binding event may extend to all dimers not yet covered by the conditions “no dimer receptor occupied” and “one of two dimer receptors occupied” [this complementary quantity corresponds to $1 - [(1 - q)^2 + 2q(1 - q)] = q^2$. It is the same as “both dimer receptors occupied” [corresponding to $\frac{2}{2} q^2(1 - q)^2 = q^2$]. These remaining dimers (to be equally occupied, but transducing differently due to negative cooperativity) then react to the endogenous agonist like those represented by the black curve in Figures 1A or 1B; the black curve is characterized by $2q (1 - q)$. To adjust for negative cooperativity, the term for the remaining dimers, $q^2$, is multiplied by the term for “one of two dimer receptors occupied,” yielding $q^2 \to q^2 \cdot 2q (1 - q)$. Note that also the first modeling corresponds to a multiplicative link: the factor chosen was $\frac{1}{2}$. This second type of modeling, where the factor $\frac{1}{2}$ of $q^2$ of the first modeling approach is replaced by $2q (1 - q)$, is characterized by the dashed brown curve in Figure 1B. Like the first type of modeling, $q^2/2$, this second type converts $q^2$ into a function that never reaches unity, thereby taking into account negative cooperativity. The sum of $2q (1 - q)$ (black curve) and of $q^2 \cdot 2q (1 - q)$ yields the solid brown curve in Figure 1B. We may learn again from this curve that at agonist concentrations of 0.032 μM and higher, more dimers with ultimately two of two $\beta_1$-ARs occupied indicate a higher inotropic response despite the presence of the antagonist, as was the case with the solid blue curve of Figure 1B. The < signs in Table 1c correspond to this “increase in inotropy”: A pure $\beta_1$-AR antagonist may enhance the inotropic action of endogenous multiple < signs $\beta_1$-AR agonists at clinically relevant concentrations above their $K_D$ ($10^{-8} M = 0.01 \mu M$). The solid blue and brown arrows on the right of the respective curve maxima in Figure 1B indicate the “increases in inotropy” due to the presence of a $\beta_1$-blocker at low concentration.

The maximum of the solid brown curve is at about $q = 0.61$, which means that the agonist concentration at this maximum is $1.56 \cdot [K_D]$ ($q = 0.61 = [0.0156]$. At higher agonist concentrations than $1.56 \cdot [K_D]$, the inotropic efficiency decreases again. Then, the added $\beta_1$-blocker, by reducing $\frac{1}{2} \cdot (1 - q)$, shifts $q$ to the left. As long as this left shift does not overcome the maximum of the brown curve at $q = 0.61$, the $\beta_1$-AR antagonist yields a positive inotropic effect of the endogenous agonists. Antagonist-induced left shifts of $q$ to values <0.61 may again worsen the positive inotropic condition: Too high $\beta_1$-AR antagonist concentrations are known to worsen chronic heart failure, which fits the prediction of our modeling approaches.

Both types of modeling suggest that in CHF (with a concentration of endogenous agonist slightly or markedly higher than its $K_D$), increased inotropic actions occur despite the presence of a low concentration of a pure $\beta_1$-AR antagonist—a phenomenon related to the reduction of negative cooperativity. This is also true if inverse agonists (e.g., carvedilol), instead of pure antagonists, prevent negative cooperativity by occupation of one dimer receptor, leaving the other open for the endogenous agonist. Note that this negative cooperativity plays hardly any role at low agonist concentrations since then the occupation of two of two dimer receptors is rather unlikely.

Our modeling approaches neither assume that agonist binding to one dimeric receptor reduces the affinity of the second receptor for the antagonists nor that antagonist binding itself induces
| Binomial formula | \(2q(1 - q) + q^2\), gray curve in Figure 1A | \(2q(1 - q) + q^2\), solid blue curve in Figure 1B | \(2q(1 - q) + q^2 \cdot 2q(1 - q)\), solid brown curve in Figure 1B |
|------------------|---------------------------------|---------------------------------|---------------------------------|
| **Endogenous agonist, \(\mu M\)** | **a** | **b** | **c** |
| 0.00032 | 6.04 | 3.09 | 5.99 | 3.08 | 5.95 | 3.07 |
| 0.001 | 17.36 | 9.30 | 16.94 | 9.18 | 16.67 | 9.09 |
| 0.0032 | 42.28 | 25.44 | 39.39 | 24.51 | 38.61 | 24.02 |
| 0.01 | 75.00 | 55.56 | 62.50 | 50.00 | 62.50 | 49.38 |
| 0.032 | 94.23 | 84.99 | 65.37 | \(<\) | 66.23 | \(<\) |
| 0.1 | 99.17 | 97.22 | 78.69 | \(<\) | 62.05 | \(<\) |
| 0.32 | 99.91 | 99.65 | 52.92 | \(<\) | 55.24 | \(<\) |
| 1 | 99.99 | 99.96 | 50.98 | \(<\) | 51.90 | \(<\) |
| 3.2 | 100.00 | 100.00 | 50.31 | \(<\) | 50.62 | \(<\) |
| 10 | 100.00 | 100.00 | 50.10 | \(<\) | 50.20 | \(<\) |
| 32 | 100.00 | 100.00 | 50.03 | \(<\) | 50.06 | \(<\) |

**TABLE 1**: Probabilities for agonist activations of one of two dimer receptors and of both of two dimer receptors, without assumed affinity reduction due to negative cooperativity [gray curve of Figure 1A; (a)], corresponding probabilities considering negative cooperativity as compression of the dashed blue curve of Figure 1A by 50% [solid blue curve of Figure 1B; (b)], and considering negative cooperativity as a product of the dashed blue curve and the black curve of Figure 1A [solid brown curve of Figure 1B; (c)] \((K_D\) of endogenous agonist \(10^{-8}\) M; \(K_A\) of antagonist \(10^{-7}\) M).
negative cooperativity. Albizu et al. (37) only observed negative cooperativity with agonists, not with antagonists.

As is known, a pure antagonist only binds to a receptor, but does not induce any receptor reaction. Strictly speaking, a reaction of antagonist binding, such as binding of this ligand to the first protomer decreasing the affinity of the same or another ligand for the second one, seems to be a contradiction in itself. Nevertheless, β₁-adrenoceptor antagonists used to treat CHF may display some agonist properties and, therefore, also can possibly induce negative cooperativity. If such an “impure” antagonist binds to one dimeric β₁-adrenoceptor and, therefore, the agonist binding to the other dimeric β₁-adrenoceptor is reduced, then the term \( q = \frac{[L]}{gK_{D} + [L]} \) is changed to \( \frac{[L]}{gK_{D} + [L]} \) with "\( g > 1 \). In other words, when \( g \) increases, \( q \) decreases. Then, the probability \( q \) of agonist binding on the x-axis in Figure 1B is shifted to the left: With higher agonist concentrations, the same condition as depicted in Figure 1B will be reached. Other sequels of our proposed modeling approaches do not have to be expected.

Correspondingly, when agonist binding to one dimeric receptor reduces the affinity of the second receptor for the antagonist, then the term \( q = \frac{[\text{endogenous agonist}]}{K_{D} + \frac{[\text{endogenous agonist}][L + \text{dimer}]}{[L]}} + \frac{[\text{endogenous agonist}] + [L] + [\text{dimer}]}{[L]} \) changes to \( q = \frac{[\text{endogenous agonist}]}{K_{D} + \frac{[\text{endogenous agonist}][L + \text{dimer}]}{[L]}} + \frac{[\text{endogenous agonist}] + [L] + [\text{dimer}]}{[L]} \) with "\( \beta > 1 \), but still \( \beta > 0 \). In other words, when \( \beta \) decreases, \( q \) slightly increases. Then, the probability \( q \) of agonist binding on the x-axis in Figure 1B is slightly shifted to the right: With a slightly higher antagonist concentration, the same condition as depicted in Figure 1B will be reached, again without any other sequels of our proposed modeling approaches.

CONCLUSION

This article explains that, despite the presence of a low concentration of a β₁-AR antagonist, a positive inotropic effect may occur in CHF. Our approach considers well-established prerequisites, i.e., (i) that the β₁-ARs are spare, (18–20), (ii) dimer receptors with activation of one receptor dimer already leading to the maximum effect (25), and (iii) that the concentration of the endogenous agonist (NA plus A) at the β₁-AR is higher than its \( K_{D} \) value (21–23). Our calculation is based on the binomial distribution and shows that, due to the negative cooperativity of the receptor dimers (25), negative inotropy is converted to positive inotropy at moderate and high concentrations of the endogenous agonist.

The following questions remain. First, both proposed modeling approaches suggest a reduction in positive inotropy again if the concentration of the β₁-adrenoceptor antagonist is so high that it shifts \( q \) too far to the left. Then \( q \) in the ascending part of the solid blue or brown curve of Figure 1B. Does this condition with decreasing benefit point to the clinical observation that too high concentrations of β₁-adrenoceptor antagonists can worsen chronic heart failure? Second, can increased and possibly harmful concentrations of β₁-adrenoceptor antagonists be estimated accurately enough on the basis of the proposed modeling approaches to avoid clinical deteriorations in patients with chronic heart failure?

Nevertheless, this article may help to eliminate the skepticism of clinicians about the use of β₁-blockers because of their supposed negative inotropic effect, since on the contrary, a positive inotropic effect can be expected for receptor-theoretical reasons. In addition, in the future, increased, and possibly harmful, concentrations of β₁-blockers leading to clinical deterioration in patients with CHF may be avoided on the basis of the proposed modeling approaches.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.

AUTHOR CONTRIBUTIONS

All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.

ACKNOWLEDGMENTS

In honor of the late Helmut Drexler M.D., Professor of Medicine, Department of Cardiology, Medical School, Hannover, Germany.

REFERENCES

1. Martin NP, Whalen EJ, Zarnah MA, Pierce KL, Leiswowitz RJ. PKA-mediated phosphorylation of the β₁-adrenergic receptor promotes G₁/G₂ switching. Cell Signal. (2004) 16:1397–403. doi: 10.1016/j.cellsig.2004.05.002
2. Lymeropoulos A, Cora N, Maning J, Brill AR, Sizova A. Signaling function of cardiac autonomic nervous system receptors: Insights from GPCR signalling universe. FEBS J. (2021) 288, 2645–59. doi: 10.1111/febs.15771
3. Staus DP, Wingler LM, Strachan RT, Rasmussen SGF, Pardon E, Ahn S, et al. Regulation of β₂-adrenergic receptor function by conformationally selective single-domain intrabodies. Mol Pharmacol. (2014) 85:472–81. doi: 10.1124/mol.113.089516
4. Liu X, Masoudi A, Khaasai A, Huang LY, Pani B, Staus DP, et al. Mechanism of β₂-AR regulation by an intracellular positive allosteric modulator. Science. (2019) 364:1283–7. doi: 10.1126/science.aaw9881
5. Ma X, Hu Y, Batebi H, Heng J, Xu J, Liu X, et al. Analysis of β₂-AR-G₁si and β₂-AR-G₁ complex formation by NMR spectroscopy. Proc Natl Acad Sci USA. (2020) 117:23096–105. doi: 10.1073/pnas.2009786117
6. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Dzavner MH, et al. (2013) 2013 ACCF/AHA guideline for the management of heart failure. A report of the American college of cardiology foundation/American heart task force on practice guidelines. Circulation. (2013) 128:324–327. doi: 10.1161/CIR.0b013e31829e8807
7. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. (2016) 37:2129–200. doi: 10.5603/KP.2016.6.0141
8. Edelmann F. Chronic heart failure. Dt Arztebl Int. (2018) 115:124–30. doi: 10.3238/arztebl.2018.0124
9. Prins KW, Neill JM, Tyler JO, Eckman PM, Duvall S. Effects of beta-blocker with-drawal in acute decompensated heart failure:
a systematic review and meta-analysis. JACC Heart Fail. (2015) 3:647–53. doi: 10.1016/j.jchf.2015.03.008

10. Kelly RA, Smith TW. Pharmacological treatment of heart failure. In: Hardman JH, Goodman Gilman A, Limbird LE, editors. Goodman Gilman's The Pharmacological Basis of Therapeutics, 9th Edn. New York, NY: London: McGraw-Hill (1996). p. 809–38.

11. Barrese V, Taglialetela M. New advances in beta-blocker therapy in heart failure. Front Physiol. (2013) 4:323. doi: 10.3389/fphys.2013.00323

12. Fröhlich H, Torres L, Täger T, Schellberg D, Corletto A, Kazmi S, et al. Bisoprolol compared with carvedilol and metoprolol succinate in the treatment of patients with chronic heart failure. Clin Res Cardiol. (2017) 106:711–21. doi: 10.1007/s00392-017-1115-0

13. López-Sendón J, Svedberg K, McMurray J, Tamargo J, Maggioni AP, Dargie H, et al. Expert consensus document on β-adrenergic receptor blockers. Eur Heart J. (2004) 25:1341–62. doi: 10.1016/j.euhj.2004.06.002

14. Mangmool S, Parichatikanond W, Kurose H. Therapeutic targets for treatment of heart failure: focus on GRKs and β-arrestins affecting βAR signaling. Front Pharmacol. (2018) 9:1336. doi: 10.3389/fphar.2018.01336

15. Wang J, Zareri C, Rockman HA. G-protein-coupled receptors in heart disease. Circ Res. (2018) 123:716–35. doi: 10.1161/CIRCRESAHA.118.311403

16. Nagamoto Y, Yoshikawa T, Kohno T, Kazumi S, et al. New advances in beta-blocker therapy in heart failure. Front Physiol. (2013) 4:323. doi: 10.3389/fphys.2013.00323

17. Du Y, Zhang M, Zhao W, Shu Y, Gao M, Zhuang Y, et al. Let-7a regulates β<sub>1</sub>-adrenoceptor signaling pathway in chronic ischemic heart failure. Oncotarget. (2017) 8:752–64. doi: 10.18632/oncotarget.14436

18. Kaumann AJ. On spare beta-adrenoceptors of inotropic effect of catecholamines in kitten ventricle. Naunyn Schmiedebergs Arch Pharmacol. (1978) 305:97–102. doi: 10.1007/BF00508277

19. Brown L, Deighton NM, Bals S, Söllmann W, Zerkowski HR, Michel MC, et al. Spare receptors for beta-adrenoceptor-mediated positive inotropic effects of catecholamines in the human heart. J Cardiovasc Pharmacol. (1992) 19:222–32. doi: 10.1097/00004788-199202000-00011

20. Du Y, Zhang M, Zhao W, Shu Y, Gao M, Zhuang Y, et al. Let-7a regulates expression of β<sub>1</sub>-adrenoceptors and forms a negative feedback circuit with the β<sub>1</sub>-adrenoceptor signaling pathway in chronic ischemic heart failure. Oncotarget. (2017) 8:752–64. doi: 10.18632/oncotarget.14436

21. Hoffmann C, Leitz MR, Oberdorf-Maass S, Lohse MJ, Klots KN. Comparative pharmacology of human β<sub>1</sub>-adrenergic receptor subtypes – characterization of stably transfected receptors in CHO cells. Naunyn-Schmiedeberg's Arch Pharmacol. (2004) 369:151–9. doi: 10.1007/s00210-003-0860-y

22. Mirruto A, Hasegawa H, Cheng H-J, Little WC, Cheng C-P, et al. Endogenous β<sub>1</sub>-adrenoceptor activation contributes to left ventricular and cardiomyocyte dysfunction in heart failure. Am J Physiol Heart Circ Physiol. (2004) 286:H2425–H2433. doi: 10.1123/ajpheart.10145.2003

23. Calebiro D, Rieken F, Wagner J, Sundwokorn T, Zabel U, Borzi A, et al. Single-molecule analysis of fluorescently labeled G-protein–coupled receptors reveals complexes with distinct dynamics and organization. Proc Natl Acad Sci USA. (2013) 110:743–8. doi: 10.1073/pnas.1205798110

24. Gherbi K, May LT, Baker JG, Briddon SJ, Hll SJ. Negative cooperativity across β<sub>1</sub>-adrenoceptor homodimers provides insights into the nature of the secondary low-affinity CGP 12177 β<sub>1</sub>-adrenoceptor binding domain. FASEB J. (2015) 29:2509–71. doi: 10.1096/fj.14-265199

25. Kerrick-Davis K, Grinde E, Cowan A, Mazurkiewicz JE. Fluorescence correlation spectroscopy analysis of serotonin, adrenergic, muscarinic, and dopamine receptor dimerization: the oligomer number puzzle. Mol Pharmacol. (2013) 84:630–42. doi: 10.1124/mol.113.108702

26. Ferré S, Casado V, Devi LA, Filizola M, Jockers R, Lohse MJ, et al. G protein–coupled receptor oligomerization revisited: functional and pharmacological perspectives. Pharmacol Rev. (2014) 66:413–34. doi: 10.1124/pr.113.008052

27. Herrick-Davis K, Grinde E, Cowan A, Mazurkiewicz JE. Fluorescence correlation spectroscopy analysis of serotonin, adrenergic, muscarinic, and dopamine receptor dimerization: the oligomer number puzzle. Mol Pharmacol. (2013) 84:630–42. doi: 10.1124/mol.113.108702

28. Ferrerri G, Marconi C, Achilli G, Caspani E, Fiocchi R, Mamprin F, et al. The heart response to exercise and circulating catecholamines in heart transplant recipients. Pflügers Arch Eur J Physiol. (2002) 443:370–6. doi: 10.1007/s004240100701

29. Baker JC. The selectivity of β-adrenoceptor agonists at human β<sub>1</sub>, β<sub>2</sub> and β<sub>3</sub>-adrenoceptors. Br J Pharmacol. (2010) 160:1048–61. doi: 10.1111/j.1476-5381.2010.07554.x

30. Black JW, Leff P. Operational models of pharmacological agonism. Proc R Soc B. (1983) 220:141–62. doi: 10.1098/rspb.1983.0093

31. Agneter E, Singer EA, Saurermann W, Feuerstein TJ. The slope parameter of concentration-response curves used as a touchstone for the existence of spare receptors. Naunyn Schmiedebergs Arch Pharmacol. (1997) 356:283–92. doi: 10.1007/PL00005552

32. Saurermann W, Feuerstein TJ. Some mathematical models for concentration-response relationships. Biometrical J. (1998) 40:865–81. doi: 10.1002/(SICI)1521-3086(199811)40:7<385::AID-BIMJ865>3.0.CO;2-4

33. Feuerstein TJ, Saurermann W. What is the opposite of a receptor reserve? Intl J Pharmacol. (2005) 1:195–202. doi: 10.1093/ijp/2005.195.202

34. Feuerstein TJ, Saurermann W, Allgaier C, Agneter E, Singer EA. New insights into receptor theory, as provided by an artificial partial agonist made-to-measure. Naunyn Schmiedebergs Arch Pharmacol. (1997) 350:1–9. doi: 10.1007/BF00180003

35. Mantovani M, Dooley DJ, Weyerbrock A, Jackisch R, Feuerstein TJ. Differential inhibitory effects of drugs acting at the noradrenergic and 5-hydroxytryptamine transporters in rat and human neocortical synaptosomes. Brit J Pharmacol. (2009) 158:1848–56. doi: 10.1111/j.1476-5381.2009.00478.x

36. Cheng Y-C, Prusoff WH. Relationship between the inhibition constant (K<sub>I</sub>) and the concentration of inhibitor which causes 50 per cent inhibition (I<sub>50</sub>) of an enzymatic reaction. Biochim Biophys Acta. (1973) 22:3099–108. doi: 10.1016/0006-2952(73)90196-2

37. Albusz I, Balestre MN, Breton C, Pin JP, Manning M, Mouillac B, et al. Probing the existence of G protein-coupled receptor dimers by positive and negative ligand-dependent cooperative binding. Mol Pharmacol. (2006) 70:1783–91. doi: 10.1124/mol.106.025684

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Feuerstein and Schlicker. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.